331 related articles for article (PubMed ID: 16729222)
1. Characteristics of substance P transport across the blood-brain barrier.
Chappa AK; Audus KL; Lunte SM
Pharm Res; 2006 Jun; 23(6):1201-8. PubMed ID: 16729222
[TBL] [Abstract][Full Text] [Related]
2. Specific binding of substance P aminoterminal heptapeptide [SP(1-7)] to mouse brain and spinal cord membranes.
Igwe OJ; Kim DC; Seybold VS; Larson AA
J Neurosci; 1990 Nov; 10(11):3653-63. PubMed ID: 1700082
[TBL] [Abstract][Full Text] [Related]
3. Binding of the novel ligand [4,5-3H-Leu10]substance P to high-affinity NK-1 receptors on guinea pig lung membranes: modulation by GTP analogs and sulfhydryl modifying agents.
Aharony D; Catanese CA; Woodhouse DP
J Pharmacol Exp Ther; 1991 Oct; 259(1):146-55. PubMed ID: 1717678
[TBL] [Abstract][Full Text] [Related]
4. Autoradiographic distribution of brain neurokinin-1/substance P receptors using a highly selective ligand [3H]-[Sar9,Met(O2)11]-substance P.
Dam TV; Martinelli B; Quirion R
Brain Res; 1990 Oct; 531(1-2):333-7. PubMed ID: 1705154
[TBL] [Abstract][Full Text] [Related]
5. Internalization of [3H]substance P analogues in NK-1 receptor transfected CHO cells.
Sagan S; Lavielle S
Biochem Biophys Res Commun; 2001 Apr; 282(4):958-64. PubMed ID: 11352645
[TBL] [Abstract][Full Text] [Related]
6. Septide: an agonist for the NK1 receptor acting at a site distinct from substance P.
Pradier L; Ménager J; Le Guern J; Bock MD; Heuillet E; Fardin V; Garret C; Doble A; Mayaux JF
Mol Pharmacol; 1994 Feb; 45(2):287-93. PubMed ID: 7509440
[TBL] [Abstract][Full Text] [Related]
7. High affinity binding of [3H]propionyl-[Met(O2)11]substance P(7-11), a tritiated septide-like peptide, in Chinese hamster ovary cells expressing human neurokinin-1 receptors and in rat submandibular glands.
Sagan S; Beaujouan JC; Torrens Y; Saffroy M; Chassaing G; Glowinski J; Lavielle S
Mol Pharmacol; 1997 Jul; 52(1):120-7. PubMed ID: 9224821
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the metabolism of substance P at the blood-brain barrier using LC-MS/MS.
Chappa AK; Cooper JD; Audus KL; Lunte SM
J Pharm Biomed Anal; 2007 Mar; 43(4):1409-15. PubMed ID: 17118606
[TBL] [Abstract][Full Text] [Related]
9. Septide and neurokinin A are high-affinity ligands on the NK-1 receptor: evidence from homologous versus heterologous binding analysis.
Hastrup H; Schwartz TW
FEBS Lett; 1996 Dec; 399(3):264-6. PubMed ID: 8985159
[TBL] [Abstract][Full Text] [Related]
10. Are biological actions of neurokinin A in the adult brain mediated by a cross-talk between the NK1 and NK2 receptors?
Tauer U; Zhao Y; Hunt SP; Culman J
Neuropharmacology; 2012 Nov; 63(6):958-65. PubMed ID: 22771977
[TBL] [Abstract][Full Text] [Related]
11. Contractile effect of tachykinins on Suncus murinus (house musk shrew) isolated ileum.
Cheng FH; Chan SW; Rudd JA
Neuropeptides; 2008; 42(5-6):671-9. PubMed ID: 18582934
[TBL] [Abstract][Full Text] [Related]
12. The N-terminal domain of substance P is required for complete homologous desensitization but not phosphorylation of the rat neurokinin-1 receptor.
Vigna SR
Neuropeptides; 2001 Feb; 35(1):24-31. PubMed ID: 11346307
[TBL] [Abstract][Full Text] [Related]
13. Role of nitric oxide and septide-insensitive NK(1) receptors in bronchoconstriction induced by aerosolised neurokinin A in guinea-pigs.
Ricciardolo FL; Trevisani M; Geppetti P; Nadel JA; Amadesi S; Bertrand C
Br J Pharmacol; 2000 Mar; 129(5):915-20. PubMed ID: 10696090
[TBL] [Abstract][Full Text] [Related]
14. Two classes of binding sites for [3H]substance P in rat cerebral cortex.
Geraghty DP; Burcher E
Brain Res; 1993 Jan; 601(1-2):34-40. PubMed ID: 7679311
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist.
Gitter BD; Bruns RF; Howbert JJ; Waters DC; Threlkeld PG; Cox LM; Nixon JA; Lobb KL; Mason NR; Stengel PW
J Pharmacol Exp Ther; 1995 Nov; 275(2):737-44. PubMed ID: 7473161
[TBL] [Abstract][Full Text] [Related]
16. Human astrocytoma cells (U-87 MG) exhibit a specific substance P binding site with the characteristics of an NK-1 receptor.
Ogo H; Kuroyanagi N; Inoue A; Nishio H; Hirai Y; Akiyama M; DiMaggio DA; Krause JE; Nakata Y
J Neurochem; 1996 Nov; 67(5):1813-20. PubMed ID: 8863485
[TBL] [Abstract][Full Text] [Related]
17. An N-terminal fragment of substance P, substance P(1-7), down-regulates neurokinin-1 binding in the mouse spinal cord.
Yukhananov RYu ; Larson AA
Neurosci Lett; 1994 Aug; 178(1):163-6. PubMed ID: 7529387
[TBL] [Abstract][Full Text] [Related]
18. The use of photolabelled peptides to localize the substance-P-binding site in the human neurokinin-1 tachykinin receptor.
Girault S; Sagan S; Bolbach G; Lavielle S; Chassaing G
Eur J Biochem; 1996 Aug; 240(1):215-22. PubMed ID: 8797856
[TBL] [Abstract][Full Text] [Related]
19. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties of FK886, a new, centrally active neurokinin-1 receptor antagonist.
Yoshino-Furukawa T; Maeda Y; Kikuchi A; Sakuma H; Imazumi K; Yamakuni H; Sogabe H; Matsuo M; Manda T; Uchida W
Biol Pharm Bull; 2013; 36(1):76-81. PubMed ID: 23302639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
